Study Evaluating the Pharmacokinetics of Tigecycline in Human Bone

Phase 1

Completed

• Conditions: Healthy Subjects

• Registration Number: NCT00376324
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

Study to examine the concentration of the study drug, tigecycline, in human bone samples following the administration of multiple doses.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-09
• Study First Submitted: 2006-09-12
• Study First Submitted QC: 2006-09-12
• Study First Posted: 2006-09-14
• Primary Completion: 2008-10
• Study Completion: 2008-10
• Status Verified: 2009-07
• Last Update Submitted: 2009-07-08
• Last Update Posted: 2009-07-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
To determine both the bone and corresponding serum concentration of tigecycline at selected time points following adminstration.	1 day